Related Experiment Video
Updated: Jun 27, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.9K
Ursolic Acid Formulations Effectively Induce Apoptosis and Limit Inflammation in the Psoriasis Models In Vitro.
Ewa Bielecka1, Natalia Zubrzycka1,2,3, Karolina Marzec1,2
1Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387 Cracow, Poland.
Biomedicines
|April 27, 2024
Summary
Ursolic acid (UA) shows promise in treating psoriasis by reducing inflammation and skin cell overgrowth. Topical bi-gel formulations of UA significantly enhance its effectiveness, offering a novel therapeutic approach.
Area of Science:
- Dermatology
- Pharmacology
- Biochemistry
Background:
- Psoriasis is a common inflammatory skin condition with challenging management.
- Novel, cost-effective, and accessible treatments are needed.
- Ursolic acid (UA), a triterpenoid, possesses anti-inflammatory and pro-apoptotic properties.
Purpose of the Study:
- To investigate the potential of ursolic acid (UA) in managing psoriasis-related inflammation and keratinocyte hyperproliferation.
- To assess the efficacy of UA in in vitro models of psoriasis.
- To develop and evaluate novel topical formulations of UA to enhance bioavailability.
Main Methods:
- In vitro studies using skin and immune cells to evaluate UA's effects on psoriasis-associated inflammation.
- Assessment of UA's impact on cytokine production (IL-6, IL-8) and psoriatic biomarkers (S100A7, S100A8, S100A9).
- Development of hybrid nano-emulsion and bi-gel topical systems to improve UA's bioavailability and effectiveness.
Main Results:
- Ursolic acid limited the production of IL-6 and IL-8 in response to inflammatory stimuli.
- UA reduced the expression of psoriatic biomarkers S100A7, S100A8, and S100A9.
- UA mitigated keratinocyte hyperproliferation via non-inflammatory apoptosis induction without negatively affecting immune cells.
- The topical bi-gel formulation of UA demonstrated superior efficacy compared to UA alone in limiting keratinocyte response.
Conclusions:
- Topical ursolic acid formulations exhibit significant anti-inflammatory activity in vitro.
- UA effectively reduces key markers of psoriasis inflammation and hyperproliferation.
- Novel topical delivery systems, particularly the bi-gel, enhance UA's therapeutic potential for psoriasis treatment.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K